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Measles has recently been the focus of accelerated disease 
control activities in sub-Saharan Africa, resulting in a 
precipitous decline in reported cases and associated deaths.1 
These activities were begun in the mid-1990s by seven African 
nations, including South Africa, and resulted in the virtual 
elimination of measles in southern Africa.2
South Africa has provided routine measles vaccination 
at 9 months of age since 1975. In 1995, the South African 
Department of Health (DoH) recommended that a second 
dose of measles vaccine be given at 18 months of age via 
routine health services, and set the goal of eliminating measles 
by 2002. To achieve this, South Africa used the strategy of 
the Pan American Health Organization.3 The first step was a 
nationwide measles vaccination campaign conducted in 1996 
and 1997, targeting all children aged 9 months to 14 years, 
which achieved 85% administrative coverage. (Administrative 
coverage is the number of doses delivered divided by the 
target population. The target population is determined from 
census projections.) Subsequently, case-based surveillance with 
laboratory confirmation of suspected cases was established 
in South Africa. In 2000, a nationwide campaign targeting all 
children aged 9 months to 4 years reported 92% administrative 
coverage. From 1996 to 2004, routine measles first-dose 
coverage remained static at 76 - 83% while routine second-dose 
coverage was 63 - 78% from 2000 to 2004. Reported measles 
incidence reflected the reported success of the 1996 and 2000 
campaigns; enhanced surveillance during 1999 - 2002 reported 
<60 measles cases annually and no associated deaths.1,2
However, measles virus was introduced in July 2003 to 
Mpumalanga and Gauteng provinces from Mozambique, 
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Objectives. Measles was virtually eliminated in South Africa 
following control activities in 1996/7. However, from July 
2003 to November 2005, 1 676 laboratory-confirmed measles 
cases were reported in South Africa. We investigated the 
outbreak’s cause and the role of HIV.
Design. We traced laboratory-confirmed case-patients residing 
in the Johannesburg metropolitan (JBM) and O R Tambo 
districts. We interviewed laboratory- or epidemiologically 
confirmed case-patients or their caregivers to determine 
vaccination status and, in JBM, HIV status. We calculated 
vaccine effectiveness using the screening method.
Setting. Household survey in JBM and O R Tambo districts.
Outcome measures. Vaccine effectiveness, case-fatality rate, and 
hospitalisations.
Results. In JBM, 109 case-patients were investigated. Of 
the 57 case-patients eligible for immunisation, 27 (47.4%) 
were vaccinated. Fourteen (12.8%) case-patients were HIV 
infected, 46 (42.2%) were HIV uninfected, and 49 (45.0%) had 
unknown HIV status. Among children aged 12 - 59 months, 
vaccine effectiveness was 85% (95% confidence interval (CI): 
63, 94) for all children, 63% for HIV infected, 75% for HIV 
uninfected, and 96% for children with unknown HIV status. 
(Confidence intervals were not calculated for sub-groups 
owing to small sample size.) In O R Tambo district, 157 case-
patients were investigated. Among the 138 case-patients 
eligible for immunisation, 41 (29.7%) were vaccinated. Vaccine 
effectiveness was 89% (95% CI 77, 95).
Conclusions. The outbreak’s primary cause was failure to 
vaccinate enough of the population to prevent endemic 
measles transmission. Although vaccine effectiveness might 
have been lower in HIV-infected than in uninfected children, 
population vaccine effectiveness remained high.
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which led to an epidemic lasting more than 2 years, with  
1 676 reported laboratory-confirmed cases; 773 (46.1%) were 
from Gauteng and 506 (30.2%) from Eastern Cape; 27 measles-
associated deaths were reported nationally. In Gauteng, 11 
measles-associated deaths occurred in institutions for children; 
8 were deaths of HIV-infected children.
In outbreak-affected provinces, teams investigated suspected 
measles cases and conducted response vaccination that 
targeted exposed children in preschools, schools and hospitals. 
In April 2004, Gauteng Province’s DoH issued a directive 
to provide a supplemental dose of measles vaccine to all 
hospitalised and institutionalised children aged 6 months to 
14 years. In addition, a national measles vaccination campaign 
targeting all children aged 9 months to 4 years was conducted 
in July 2004; reported administrative coverage was 102% in 
Gauteng but only 90% in Eastern Cape. Following this national 
campaign, measles virus transmission in Gauteng decreased, 
with the final case reported in May 2005. In contrast, measles 
transmission had not started in Eastern Cape until November 
2004, months after the national campaign. To stop the spread 
of disease, a second province-wide vaccination campaign was 
conducted in Eastern Cape in May 2005, targeting children 
aged 6 months to 14 years and achieving 86% administrative 
coverage; nevertheless, measles virus transmission continued 
in the province until November 2005. This was the first large 
laboratory-confirmed measles outbreak following near-
elimination in a setting with high HIV prevalence; in 2004, 
HIV seroprevalence in South Africa was estimated at 29.5% 
among antenatal clinic attendees.4 (HIV-infected children 
have a higher rate of primary measles vaccine failure than 
HIV-uninfected children.5) Questions have been raised as to 
whether the decreased efficacy of measles vaccine reported 
among HIV-infected children could affect the ability of high 
HIV-prevalence countries to achieve and sustain interruption 
of endemic measles virus transmission.5,6 We report on field 
investigations in two provinces to determine the cause of South 
Africa’s measles outbreak and the role that HIV infection might 
have played in measles virus transmission.
Methods
We reviewed vaccination coverage data from 2000 to 2004 
and case-based surveillance data for cases with date of rash 
onset falling between July 2003 and June 2005. Serum samples 
were collected for all suspected measles cases and sent to the 
National Institute for Communicable Diseases for analysis 
of measles IgM antibody using Enzygnost (Dade-Behring, 
Marburg, Germany) diagnostic kits.
Definitions
For surveillance purposes, the South African definition of 
a laboratory-confirmed measles case-patient (LCMCP) is a 
person with fever, rash, and measles IgM-positive serum. In 
addition, we defined an epidemiologically confirmed measles 
case-patient (ECMCP) as a person with fever, rash, and at least 
1 of 3 symptoms (cough, coryza or conjunctivitis), who had 
had contact with a LCMCP. A measles-associated death was 
defined as death of a LCMCP or an ECMCP within 30 days of 
rash onset; this death must not have obviously resulted from 
another cause, e.g. trauma.7 A case-patient was considered 
vaccinated if the respondent provided documentation or 
history of receipt of one or more doses of measles-containing 
vaccine at least 30 days prior to rash onset. HIV status of 
a case-patient or case-patient’s mother was determined by 
respondent-provided history or documentation of HIV test 
results. In South Africa, HIV PCR is available for children <15 
months of age, and HIV ELISA is used to test older children 
and adults. Treatment with vitamin A was assessed by showing 
a vitamin A capsule to the respondent and asking how many 
capsules the case-patient had received during the illness.
Location
We selected two districts in which to conduct field 
investigations: the Johannesburg metropolitan district (JBM) in 
Gauteng province (the source of the largest absolute number 
of measles cases reported during the outbreak) and O R Tambo 
district in Eastern Cape province, which was the source of over 
half of all LCMCPs reported nationwide in 2005.
Gauteng province. From 25 May to 3 June 2005, we 
conducted an investigation of LCMCPs with rash onset 
between 1 July 2004 and 30 May 2005, residing in JBM 
and traced through available address information. We also 
investigated any household or school contacts meeting the 
ECMCP case definition identified during our investigation. 
We queried case-patients or their caregivers regarding the HIV 
status of the case-patient and the case-patient’s mother, and 
obtained informed consent from all respondents.
Eastern Cape province. From 17 to 30 May 2005, a field 
investigation was conducted in O R Tambo district in all 
communities that reported LCMCPs with rash onset between 
1 April and 30 May 2005. LCMCPs were interviewed and a 
house-to-house search was conducted in each case-patient’s 
community to find ECMCPs with rash onset between 1 January 
and 30 May 2005.
Vaccine effectiveness
Vaccine effectiveness (VE) was calculated using the screening 
method with the formula VE=1-[PCV/(1-PCV)x(1-PPV)/PPV], 
where PCV refers to the percentage of cases vaccinated and 
PPV refers to the percentage of the population vaccinated.8 
We confined our analysis to cases aged 12 - 59 months at the 
time of rash onset and our comparison population to this same 
age group, i.e. birth cohorts vaccinated in 2000 - 2004. Based 
on provincial routine measles first-dose vaccination coverage 
rates from 2000 to 2004, the PPV was estimated to be 80% in 
both Gauteng and Eastern Cape. Because some case-patients 
reported receiving vaccinations during campaigns only, we 
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performed sensitivity analyses using an estimate of 90% as the 
PPV to account for the potential increase in the PPV following 
campaigns. We also calculated vaccine effectiveness among 
HIV-infected children, HIV-uninfected children, and children of 
unknown HIV status aged 12 - 59 months, assuming that there 
was no difference in age at vaccination or vaccination coverage 
between these groups.
Data analysis
Data were entered and analysed using EpiInfo v3.3.2 software 
(CDC, Atlanta, GA, USA). Calculation of vaccine effectiveness 
and confidence intervals was conducted using SAS 9.1 (SAS 
Institute, Cary, NC, USA). Confidence intervals were not 
calculated for sub-groups because of the small sample sizes.
Results
Gauteng province
From 1 July 2004 to 30 May 2005, 454 LCMCPs were reported 
to the surveillance system from Gauteng province. Of these 
454, 349 (76.9%) were reported from JBM (Fig. 1). Age 
distribution of the 349 LCMCPs from JBM is shown in Table I.
Address information to permit follow-up was available for 
203 of the 349 LCMCPs. Among these 203, 2 refused consent, 
107 were not found at the address given, and 94 were located 
and agreed to complete our questionnaire. While investigating 
the latter 94 cases, we identified an additional 15 ECMCPs for 
a total of 109 measles case-patients investigated (Table I). Fifty-
seven (52.3%) case-patients reported having been hospitalised 
for measles, and 7 (6.4%) measles-associated deaths were 
reported to have occurred among the investigated case-
patients. Among the 57 case-patients ≥9 months who were 
eligible for measles vaccination, 27 (47.4%) provided either 
documentation or a history of measles vaccination – leaving 
52.6% of vaccine-eligible case-patients unvaccinated (Fig. 2).
Of the 109 investigated case-patients, 57 (52.3%) were 
hospitalised with measles and 44 (77.2%) reported having been 
isolated upon hospital admission. All 109 investigated case-
patients visited health care facilities, and 48 (44%) reported 
having received ≥1 dose of vitamin A during their measles 
illness.
Among the 109 case-patients investigated, caregivers 
reported that 14 (12.8%) were HIV infected, 46 (42.2%) were 
HIV uninfected, and 49 (45.0%) did not know their HIV status. 
HIV-infected case-patients ranged in age from 3 months to 
32 years. Twenty-nine (26.6%) case-patients’ mothers were 
reported to be HIV infected, 47 (43.1%) were reported to be 
HIV uninfected, and 33 (30.3%) respondents did not know the 
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Table I. Age distribution of measles case-patients in investigated districts from case-based surveillance and field investigation. 
Johannesburg Metro District: 1 July 2004 - 30 May 2005. O R Tambo District: 1 January 2005 - 30 May 2005
             Age group, N (%)
District      <9 months            9 - 11 months          1 - 4 years         5 - 14 years      ≥ 15 years          Unknown             Total
Johannesburg      123 (34.9)              70 (19.9)                19 (5.4)         49 (13.9)      10 (2.3)               78 (22.3)              349
Metro (surveillance)
Johannesburg      52 (47.7)               12 (11.0)                 19 (17.4)         21 (19.3)       5 (4.6)                0 (0)              109
Metro (investigation)
O R Tambo      52 (17.2)               41 (13.6)                39 (12.9)         142 (47.0)       28 (9.3)              0 (0)              302
(surveillance)
O R Tambo      19 (12.1)               14 (8.9)                30 (19.1)         85 (54.1)       9 (5.7)                0 (0)              157
(investigation)
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Fig. 1. Laboratory-confirmed measles cases by week of rash onset in  














































Fig. 2. Vaccination status of investigated measles case-patients by age 
group.
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HIV status of the case-patient’s mother. Among the 83 case-
patients aged <59 months at rash onset and therefore probably 
exposed to HIV only via maternal infection, caregivers 
reported that 9 (10.8%) were HIV infected, 40 (48.2%) were 
HIV uninfected, and 34 (41%) were of unknown HIV status. 
All 14 (100%) HIV-infected case-patients were hospitalised 
with measles, and 2 (14.3%) died. Twenty-eight (60.9%) of the 
46 known HIV-uninfected case-patients were hospitalised, 
and 2 (4.3%) died. HIV-infected case-patients were 1.6 times 
more likely to be hospitalised than known HIV-uninfected 
case-patients (p=0.003). The difference in risk of death between 
HIV-infected case-patients and HIV-uninfected case-patients 
was not statistically significant (risk ratio (RR)=3.3, 95% CI 0.5, 
21.2).
Among the 19 investigated case-patients aged 12 - 59 
months, 7 (36.8%) were vaccinated. Vaccine effectiveness 
among all children aged 12 - 59 months was estimated to be 
85% (95% CI: 63, 94) assuming the PPV to be 80% (Table II). 
Among the 5 HIV-infected case-patients in this age group, 3 
(60%) were vaccinated, and vaccine effectiveness was estimated 
to be 63%. Three (50%) of the 6 HIV-uninfected case-patients 
were vaccinated and vaccine effectiveness was estimated to be 
75%. One (12.5%) of 8 case-patients of unknown HIV status 
was vaccinated, and vaccine effectiveness was estimated to 
be 96%. If we assume that the campaign increased the PPV to 
90%, vaccine effectiveness increased to 94% (95% CI 84, 97) for 
all children aged 12 - 59 months, 83% for HIV-infected children, 
90% for HIV-uninfected children, and 98% for children of 
unknown HIV status.
Eastern Cape province
From 1 January to 30 May 2005, 417 LCMCPs were reported 
to the surveillance system from Eastern Cape province, of 
whom 302 (72.4%) were reported in O R Tambo district (Fig. 1). 
Information on age was available for all case-patients (Table I).
Seventy LCMCPs with rash onset between 1 April and 
30 May 2005 and 87 ECMCPs identified during the field 
investigation were interviewed. Seventy-nine (50.3%) of these 
patients were hospitalised for measles, and 8 (5.1%) measles-
associated deaths were reported among the investigated 
case-patients. Of the 138 case-patients ≥9 months at the time 
of rash onset and eligible for routine measles vaccination, 41 
(29.7%) provided either documentation or a history of measles 
vaccination, leaving 70.3% of vaccine-eligible case-patients 
unvaccinated (Fig. 2). Among the 30 case-patients aged 12 - 59 
months, only 9 (30.0%) provided documentation or a history 
of measles vaccination. Vaccine effectiveness in children aged 
12 - 59 months was estimated to be 89% (95% CI 77, 95) in O R 
Tambo district, assuming the PPV to be 80%, and 95% (95% CI 
90, 98) assuming the PPV to be 90%.
Among the 131 investigated case-patients who visited 
health care facilities, 60 (45.8%) received ≥1 dose of vitamin A 
during their measles illness. Among the 79 case-patients who 
were hospitalised, 46 (58.2%) reported having been placed in 
isolation.
Discussion
The primary cause of the measles outbreak in South Africa was 
the accumulation of susceptible children due to low routine 
immunisation coverage: 65% of vaccine-eligible case-patients 
interviewed in two districts born since the initial 1996 national 
campaign reported no measles vaccination in routine services 
or campaigns. This finding is consistent with reports of routine 
immunisation coverage of <83% since 2000. Although follow-
up campaigns in 2000 and 2004 reported 92% administrative 
coverage nationally, these figures might have overestimated 
true coverage owing to inaccurate census estimates of the 
target populations. This tendency mirrors experience from the 
Americas, where relatively low routine and campaign coverage 
following years without measles transmission led to large 
outbreaks once the virus was reintroduced,9 which emphasises 
the importance of maintaining a very high population 
immunity even in the absence of a circulating virus.10
Our investigations supported national surveillance data 
in finding a substantial difference in the age distribution of 
measles case-patients between the two districts (Table I). The 
Table II. Percentage of cases vaccinated (PCV) and vaccine effectiveness (VE) assuming percentage of population vaccinated 
(PPV) = 80% for investigated measles case-patients aged 12 - 59 months, Johannesburg Metro District, 1 July 2004 - 30 May 
2005
   N  N (12 - 59 mo.)   PCV       VE       95% CI
All case-patients  109           19   36.8%       85%       63 - 94%
Known HIV-infected 14           5   60%       63%            *
case-patients
Known HIV-uninfected  46           6   50%       75%            *
case-patients
Case-patients with   49           8   12.5%       96%            *
unknown HIV status
*Owing to the small sample size, confidence intervals were not calculated.
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JBM outbreak primarily affected children <1 year old, while 
the O R Tambo outbreak affected children aged 5 - 14 years. 
Factors that could have lowered the age of measles acquisition 
in JBM district include high population density, poor maternal 
antibody transfer in HIV-exposed infants, and outbreaks in 
children’s institutions.11 In O R Tambo district, historically 
low routine measles vaccination coverage and poor campaign 
performance might have left more school-age children 
susceptible to measles virus.
The World Health Organization (WHO) and United 
Nations Children’s Fund (UNICEF) Integrated Management 
of Childhood Illness guidelines recommend 2 doses of 
vitamin A given 24 hours apart to reduce measles mortality.12 
However, in this investigation, less than half of the children 
presenting to health facilities reported receiving any vitamin 
A. Isolation of suspected measles cases limits nosocomial 
measles transmission.13 Measles transmission probably 
occurred in institutions for children and health facilities in 
Gauteng province, as 58 measles cases were reported from 
these institutions, and isolation measures in the health facilities 
visited were inadequate. As with previous measles outbreaks, 
there is considerable need for more extensive therapeutic use of 
vitamin A and greater use of respiratory isolation.13,14
Maternal HIV infection might have contributed to measles 
virus transmission in JBM via reduced placental measles IgG 
transfer.11 The maximum expected HIV prevalence for the 
population of children aged <5 years in Gauteng province 
is 10%, given the 2004 antenatal clinic prevalence estimates 
of 33.1% in Gauteng (case-patient), and assuming 30% 
mother-to-child transmission.15 Prevention-of-mother-to-child-
transmission (PMTCT) programmes might have reduced 
mother-to-child HIV transmission further in Gauteng,16 
and higher mortality among HIV-infected children might 
also have reduced the proportion of HIV-infected children 
in the province. However, because we used facility-based 
surveillance to identify case-patients, HIV-infected measles 
case-patients might have been over-represented. Therefore, the 
rate of reported HIV infection of 10.8% among measles case-
patients from JBM may reflect increased measles prevalence or 
morbidity in children with HIV, a bias in case finding, or a mix 
of these and other factors.
HIV infection among case-patients might have contributed 
to the morbidity and mortality associated with the Gauteng 
outbreak; 100% of the patients we investigated who were 
known to be HIV infected were hospitalised, compared with 
only 60.9% of known HIV-uninfected patients. This was the 
only statistically significant finding suggestive of an increase 
in measles morbidity attributable to HIV infection. Our higher 
case fatality rate (CFR) among HIV-infected patients was not 
statistically significant but is consistent with other findings 
of increased measles CFR in HIV-infected children.17 The 
decreased point estimate of vaccine effectiveness among HIV-
infected children of 63% is consistent with reported estimates 
of lower measles vaccine effectiveness among HIV-infected 
children. Despite the possible decrease in vaccine effectiveness 
among HIV-infected children, overall vaccine effectiveness 
in Gauteng province remained relatively high at 85%, which 
suggests that decreased vaccine effectiveness in HIV-infected 
children should not pose a threat to regional or global measles 
mortality reduction goals and is consistent with modelling 
studies.18
For VE estimates, we chose to use a PPV of 80%. This 
PPV, based upon reported one-dose coverage, probably 
underestimates the true proportion of the population 
vaccinated. The primary purpose of calculating VE in 
our investigation was to ascertain the minimum VE. As 
demonstrated by our sensitivity analysis, a higher estimate 
of PPV would result in higher VE, therefore supporting our 
conclusion that vaccine failure did not play a substantial role in 
the outbreak.
Despite the activities of outbreak response teams, measles 
virus transmission continued until province-wide measles 
campaigns had been conducted. Vaccination of contacts alone 
has been shown to be ineffective in stopping transmission of 
measles in resource-limited settings.19 Prompt initiation of a 
wide age-range campaign in affected districts or provinces 
may be a more effective use of resources in halting measles 
transmission.20 Factors that might have resulted in shorter 
duration of the outbreak in Eastern Cape than in Gauteng 
include lower population density and earlier intervention with 
a wide age-range campaign.
There were several limitations to these field investigations. 
Firstly, small sample sizes made it difficult to detect differences 
among sub-groups and might have increased the effect of 
misclassification on VE estimates. Secondly, surveillance data 
from health facilities formed the basis of our investigations; 
but cases presenting to health facilities might not have been 
representative of all measles cases, particularly regarding 
age and HIV status. Thirdly, we were unable to locate more 
than half of the LCMCPs in Gauteng. Lastly, HIV status and 
vaccination status were determined by respondent report, and 
responses might have been affected by a social desirability 
bias. Additionally, unknown HIV status might have been a 
better marker of lack of access to care than HIV status, as 
only 1 child in this subgroup had been vaccinated prior to the 
outbreak. Mothers of infants of unknown HIV status were 
also more likely to be of unknown HIV status. Consequently, 
the increased VE among children with unknown HIV status 
is probably a mathematical artefact of the screening method, 
driven by a low PCV of 12.5%.
Conclusions
Our investigations showed the importance of maintaining 
high population immunity by means of routine immunisation 
services to prevent transmission following importation of the 
measles virus. Although HIV infection in measles case-patients 
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might have contributed to outbreak-associated morbidity 
and mortality, high population vaccine effectiveness was 
maintained. Our investigation also revealed that vitamin A and 
respiratory isolation continue to be underutilised in measles 
outbreaks, and that case investigation with contact vaccination 
is not effective in stopping measles virus transmission.
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